ATG4B and chronic myelogenous leukemia, BCR-ABL1 positive: For example, ATG4B is highly expressed in lung cancer tissues (Wu et al., 2016b); targeting Atg4B inhibits autophagy and reduces tumor cell survival in chronic myeloid leukemia (Rothe et al., 2014); overexpression of the dominant negative mutant Atg4BC74A in prostate cancer inhibits cell proliferation and enhances chemotherapeutic drug sensitivity (Tran et al., 2013).